GlassScriptPhysician profile
Samuel Ganz
NPI 1447591714
$2,519.71
in general payments reported to CMS, 2019-2025
22 companies · $357 in 2025
The $357 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $576 · 2020: $68.81 · 2021: $485 · 2022: $294 · 2023: $411 · 2024: $328 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,096.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,095.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $290.00 | 2024-2025 | |
| Horizon Therapeutics Plc | $274.83 | 2022-2023 | Krystexxa, Tepezza |
| Glaxosmithkline, LLC. | $266.55 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.05 | 2019-2024 | Jardiance |
| Stryker Corporation | $164.09 | 2021 | |
| Janssen Pharmaceuticals, INC | $163.84 | 2019-2021 | |
| Abbvie INC. | $142.55 | 2025 | |
| Genzyme Corporation | $141.00 | 2023 | |
| Baxter Healthcare | $125.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $124.46 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $121.27 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $119.81 | 2023 | Ilumya |
| Amgen INC. | $108.12 | 2019-2025 | Krystexxa, Evenity |
| Dendreon Pharmaceuticals LLC | $49.71 | 2025 | Provenge |
| Medtronic, INC. | $45.10 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $36.45 | 2019 | |
| Novo Nordisk INC | $35.58 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $32.81 | 2021 | |
| Lilly USA, LLC | $31.45 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.30 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $17.56 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Ganz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.